

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Running title: Azithromycin for COVID-19

RECOVERY Collaborative Group*

*The writing committee and trial steering committee are listed at the end of this manuscript and a complete list of collaborators in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix.

Correspondence to: Professor Peter W Horby and Professor Martin J Landray, RECOVERY Central Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom.

Email: recoverytrial@ndph.ox.ac.uk

Azithromycin for COVID-19

23 **SUMMARY**

24 **Background:** Azithromycin has been proposed as a treatment for COVID-19 on the
25 basis of its immunomodulatory actions. We evaluated the efficacy and safety of
26 azithromycin in hospitalised patients with COVID-19.

27 **Methods:** In this randomised, controlled, open-label, adaptive platform trial, several
28 possible treatments were compared with usual care in patients hospitalised with
29 COVID-19 in the UK. Eligible and consenting patients were randomly allocated to either
30 usual standard of care alone or usual standard of care plus azithromycin 500 mg once
31 daily by mouth or intravenously for 10 days or until discharge (or one of the other
32 treatment arms). Patients were twice as likely to be randomised to usual care as to any
33 of the active treatment groups. The primary outcome was 28-day mortality. The trial is
34 registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

35 **Findings:** Between 7 April and 27 November 2020, 2582 patients were randomly
36 allocated to receive azithromycin and 5182 patients to receive usual care alone. Overall,
37 496 (19%) patients allocated to azithromycin and 997 (19%) patients allocated to usual
38 care died within 28 days (rate ratio 1.00; 95% confidence interval [CI] 0.90-1.12;
39 $p=0.99$). Consistent results were seen in all pre-specified subgroups of patients. There
40 was no difference in duration of hospitalisation (median 12 days vs. 13 days) or the
41 proportion of patients discharged from hospital alive within 28 days (60% vs. 59%; rate
42 ratio 1.03; 95% CI 0.97-1.10; $p=0.29$). Among those not on invasive mechanical
43 ventilation at baseline, there was no difference in the proportion meeting the composite

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Azithromycin for COVID-19

44 endpoint of invasive mechanical ventilation or death (21% vs. 22%; risk ratio 0.97; 95%
45 CI 0.89-1.07; $p=0.54$).

46 **Interpretation:** In patients hospitalised with COVID-19, azithromycin did not provide
47 any clinical benefit. Azithromycin use in patients hospitalised with COVID-19 should be
48 restricted to patients where there is a clear antimicrobial indication.

49 **Funding:** UK Research and Innovation (Medical Research Council) and National
50 Institute of Health Research (Grant ref: MC_PC_19056).

51 **Keywords:** COVID-19, azithromycin, clinical trial.

52

53 **NOTE:**

54 Enrolment to the azithromycin arm of the RECOVERY trial was closed on 27 November
55 2020. Here we report the preliminary findings based on a data cut on 30 November
56 2020. Final results will be made available after the last patient has completed the 28-
57 day follow-up period for the primary outcome on 25 December 2020. As with previous
58 reports, we anticipate >99% follow-up of all patients due to the linkage with routine NHS
59 data. With 1483 deaths among a total of 7764 patients included in the current report, the
60 findings are unlikely to change in any material way.

61

Azithromycin for COVID-19

62 INTRODUCTION

63 A substantial proportion of individuals infected with severe acute respiratory syndrome
64 coronavirus 2 (SARS-CoV-2) develop a respiratory illness requiring hospital care, which
65 can progress to critical illness with hypoxic respiratory failure requiring prolonged
66 ventilatory support. Among COVID-19 patients admitted to UK hospitals in the first wave
67 of the epidemic, the case fatality rate was over 26%, and in excess of 37% in patients
68 requiring invasive mechanical ventilation.¹

69 Among patients with severe COVID-19, the host immune response is thought to play a
70 key role in driving an acute pneumonic process with diffuse alveolar damage,
71 inflammatory infiltrates, and microvascular thrombosis.² The beneficial effects of
72 dexamethasone and other corticosteroids in patients with hypoxic lung damage suggest
73 that other drugs that suppress or modulate the immune system may provide additional
74 improvements in clinical outcomes.^{3,4}

75 Macrolide antibiotics, such as azithromycin, clarithromycin and erythromycin, are widely
76 available and their safety is well established. In addition to antibacterial properties, they
77 are known to have immunomodulatory activity, decreasing production of pro-
78 inflammatory cytokines and inhibiting neutrophil activation.⁵⁻⁷ They are widely used both
79 in bacterial pneumonia due to their antimicrobial activity and in chronic inflammatory
80 lung disease due to their immunomodulatory effects.^{8,9} In addition, azithromycin has *in*
81 *vitro* antiviral activity against a range of viruses including SARS-CoV-2.^{10,11}

82 The use of macrolides in influenza-associated pneumonia has been associated with a
83 faster reduction in inflammatory cytokines and, in combination with naproxen,

Azithromycin for COVID-19

84 decreased mortality.¹²⁻¹⁴ However, randomised trials have so far failed to demonstrate
85 convincing clinical benefit of macrolides in COVID-19.¹⁵⁻¹⁷ Here we report the
86 preliminary results of a randomised controlled trial of azithromycin in patients
87 hospitalised with COVID-19.

88

89 **METHODS**

90 **Study design and participants**

91 The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigator-
92 initiated, individually randomised, controlled, open-label, adaptive platform trial to
93 evaluate the effects of potential treatments in patients hospitalised with COVID-19.
94 Details of the trial design and results for other possible treatments (dexamethasone,
95 hydroxychloroquine, and lopinavir-ritonavir) have been published previously.^{3,18,19} The
96 trial is underway at 176 hospitals in the United Kingdom (appendix pp 2-22), supported
97 by the National Institute for Health Research Clinical Research Network. The trial is
98 coordinated by the Nuffield Department of Population Health at the University of Oxford
99 (Oxford, UK), the trial sponsor. The trial is conducted in accordance with the principles
100 of the International Conference on Harmonisation–Good Clinical Practice guidelines and
101 approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA)
102 and the Cambridge East Research Ethics Committee (ref: 20/EE/0101). The protocol,
103 statistical analysis plan, and additional information are available on the study website
104 www.recoverytrial.net.

Azithromycin for COVID-19

105 Although the azithromycin, dexamethasone, hydroxychloroquine, and lopinavir-ritonavir
106 arms have now been stopped, the trial continues to study the effects of tocilizumab,
107 convalescent plasma, REGEN-COV2 (a combination of two monoclonal antibodies
108 directed against SARS-CoV-2 spike glycoprotein), aspirin, and colchicine. Other
109 treatments may be studied in future.

110 Patients admitted to hospital were eligible for the study if they had clinically suspected
111 or laboratory confirmed SARS-CoV-2 infection and no medical history that might, in the
112 opinion of the attending clinician, put the patient at significant risk if they were to
113 participate in the trial. Initially, recruitment was limited to patients aged at least 18 years
114 but from 9 May 2020, the age limit was removed. Patients with known prolonged QTc
115 interval or hypersensitivity to a macrolide antibiotic and those already receiving
116 chloroquine or hydroxychloroquine were excluded from being randomised between
117 azithromycin and usual care. Written informed consent was obtained from all patients,
118 or a legal representative if they were too unwell or unable to provide consent.

119 **Randomisation and masking**

120 Baseline data were collected using a web-based case report form that included
121 demographics, level of respiratory support, major comorbidities, suitability of the study
122 treatment for a particular patient, and treatment availability at the study site (appendix
123 pp 26-28). Eligible and consenting patients were assigned to either usual standard of
124 care or usual standard of care plus azithromycin or one of the other available
125 RECOVERY treatment arms using web-based simple (unstratified) randomisation with
126 allocation concealed until after randomisation (appendix pp 23-25). Randomisation to

Azithromycin for COVID-19

127 usual care was twice that of any of the active arms the patient was eligible for (e.g. 2:1
128 in favour of usual care if the patient was eligible for only one active arm, 2:1:1 if the
129 patient was eligible for two active arms). For some patients, azithromycin was
130 unavailable at the hospital at the time of enrolment or if a macrolide antibiotic was
131 considered by the managing physician to be either definitely indicated or definitely
132 contraindicated. These patients were excluded from the randomised comparison
133 between azithromycin and usual care. Patients allocated to azithromycin were to
134 receive azithromycin 500 mg by mouth, nasogastric tube, or intravenous injection once
135 daily for 10 days or until discharge, if sooner. Allocated treatment was prescribed by the
136 managing doctor. Participants and local study staff were not masked to the allocated
137 treatment. The Steering Committee, investigators, and all others involved in the trial
138 were masked to the outcome data during the trial.

139 **Procedures**

140 A single online follow-up form was completed when participants were discharged, had
141 died or at 28 days after randomisation, whichever occurred earliest (appendix p 29-35).
142 Information was recorded on adherence to allocated study treatment, receipt of other
143 COVID-19 treatments, duration of admission, receipt of respiratory or renal support, and
144 vital status (including cause of death). In addition, routine healthcare and registry data
145 were obtained including information on vital status (with date and cause of death),
146 discharge from hospital, receipt of respiratory support, or renal replacement therapy.

147 **Outcomes**

Azithromycin for COVID-19

148 Outcomes were assessed at 28 days after randomisation, with further analyses
149 specified at 6 months. The primary outcome was all-cause mortality. Secondary
150 outcomes were time to discharge from hospital, and, among patients not on invasive
151 mechanical ventilation at randomisation, invasive mechanical ventilation (including
152 extra-corporal membrane oxygenation) or death. Prespecified subsidiary clinical
153 outcomes were cause-specific mortality, use of haemodialysis or haemofiltration, major
154 cardiac arrhythmia (recorded in a subset), and receipt and duration of ventilation.
155 Among those on invasive mechanical ventilation at randomisation, a subsidiary clinical
156 outcome of successful cessation of invasive mechanical ventilation was defined as
157 cessation within (and survival to) 28 days. Information on suspected serious adverse
158 reactions was collected in an expedited fashion to comply with regulatory requirements.

159 **Statistical Analysis**

160 An intention-to-treat comparison was conducted between patients randomised to
161 azithromycin and patients randomised to usual care but for whom azithromycin was
162 both available and suitable as a treatment. For the primary outcome of 28-day mortality,
163 the log-rank observed minus expected statistic and its variance were used to both test
164 the null hypothesis of equal survival curves (i.e., the log-rank test) and to calculate the
165 one-step estimate of the average mortality rate ratio. We constructed Kaplan-Meier
166 survival curves to display cumulative mortality over the 28-day period. The 2059
167 patients (27%) who had not been followed for 28 days and were not known to have died
168 by the time of the data cut for this preliminary analysis (30 November 2020) were either
169 censored on 30 November 2020 or, if they had already been discharged alive, were
170 right-censored for mortality at day 29 (that is, in the absence of any information to the

Azithromycin for COVID-19

171 contrary they were assumed to have survived 28 days). [Note: This censoring rule will
172 not be necessary for the final report.] We used similar methods to analyse time to
173 hospital discharge and successful cessation of invasive mechanical ventilation, with
174 patients who died in hospital right-censored on day 29. Median time to discharge was
175 derived from Kaplan-Meier estimates. For the pre-specified composite secondary
176 outcome of invasive mechanical ventilation or death within 28 days (among those not
177 receiving invasive mechanical ventilation at randomisation) and the subsidiary clinical
178 outcomes of receipt of ventilation and use of haemodialysis or haemofiltration, the
179 precise dates were not available and so the risk ratio was estimated instead.

180 Prespecified analyses of the primary outcome were performed separately in seven
181 subgroups defined by characteristics at randomisation: age, sex, ethnicity, level of
182 respiratory support, days since symptom onset, use of corticosteroids, and predicted
183 28-day mortality risk (appendix p 26). Observed effects within subgroup categories were
184 compared using a chi-squared test for heterogeneity or trend, in accordance with the
185 prespecified analysis plan.

186 Estimates of rate and risk ratios are shown with 95% confidence intervals. All p-values
187 are 2-sided and are shown without adjustment for multiple testing. The full database is
188 held by the study team which collected the data from study sites and performed the
189 analyses at the Nuffield Department of Population Health, University of Oxford (Oxford,
190 UK).

191 As stated in the protocol, appropriate sample sizes could not be estimated when the trial
192 was being planned at the start of the COVID-19 pandemic (appendix p 26). As the trial

Azithromycin for COVID-19

193 progressed, the trial steering committee, whose members were unaware of the results
194 of the trial comparisons, determined that sufficient patients should be enrolled to provide
195 at least 90% power at a two-sided p-value of 0.01 to detect a clinically relevant
196 proportional reduction in the primary outcome of 20% between the two groups.
197 Consequently, on 27 November 2020, the steering committee, blinded to the results,
198 closed recruitment to the azithromycin comparison as sufficient patients had been
199 enrolled.

200 Analyses were performed using SAS version 9.4 and R version 3.4.0. The trial is
201 registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

202 **Role of the funding source**

203 The funder of the study had no role in study design, data collection, data analysis, data
204 interpretation, or writing of the report. The corresponding authors had full access to all
205 the data in the study and had final responsibility for the decision to submit for
206 publication.

207

208 **RESULTS**

209 Between 7 April 2020 and 27 November 2020, 9434 (57%) of 16443 patients enrolled
210 into the RECOVERY trial were eligible to be randomly allocated to azithromycin (that is
211 azithromycin was available in the hospital at the time and the attending clinician was of
212 the opinion that the patient had no known indication for or contraindication to
213 azithromycin, figure 1; appendix p 38). 2582 patients were randomly allocated to

Azithromycin for COVID-19

214 azithromycin and 5182 were randomly allocated to usual care, with the remainder being
215 randomly allocated to one of the other treatment arms. The mean age of study
216 participants in this comparison was 65.3 years (SD 15.7) and the median time since
217 symptom onset was 8 days (IQR 5 to 11 days) (table 1; appendix p 38).

218 Among the 5910 (76%) patients for whom a follow-up form has been completed to date,
219 1760 (89%) allocated to azithromycin vs. 55 (1%) allocated to usual care received at
220 least one dose, and 1836 (92%) vs. 606 (15%) received any macrolide antibiotic (figure
221 1; appendix p 39). The median duration of treatment with azithromycin was 6 days (IQR
222 3-9 days). Use of other treatments for COVID-19 was similar among patients allocated
223 azithromycin and among those allocated usual care, with nearly one half receiving a
224 corticosteroid, about one-fifth receiving remdesivir, and one-fifth receiving convalescent
225 plasma.

226 We observed no significant difference in the proportion of patients who met the primary
227 outcome of 28-day mortality between the two randomised groups (496 [19%] patients in
228 the azithromycin group vs. 997 (19%) patients in the usual care group; rate ratio 1.00;
229 95% confidence interval [CI], 0.90 to 1.12; $p=0.99$; figure 2). We observed similar
230 results across all pre-specified subgroups (figure 3). In an exploratory analysis restricted
231 to the 6916 (89%) patients with a positive SARS-CoV-2 test result, the result was similar
232 (rate ratio 0.99, 95% CI 0.88 to 1.10; $p=0.81$).

233 Allocation to azithromycin was associated with a similar time until discharge from
234 hospital alive as usual care (median 12 days vs. 13 days) and a similar probability of
235 discharge alive within 28 days (60% vs. 59%, rate ratio 1.03, 95% CI 0.97 to 1.10,

Azithromycin for COVID-19

236 p=0.29) (Table 2). Among those not on invasive mechanical ventilation at baseline, the
237 number of patients progressing to the pre-specified composite secondary outcome of
238 invasive mechanical ventilation or death among those allocated to azithromycin was
239 similar to that among those allocated to usual care (21% vs. 22%, risk ratio 0.97, 95%
240 CI 0.89 to 1.07, p=0.54). Allowing for multiple testing in interpretation of the results,
241 there was no evidence that the effect of allocation to azithromycin vs. usual care on time
242 until discharge from hospital alive or on invasive mechanical ventilation or death differed
243 between pre-specified subgroups of patients (appendix p 43-44).

244 We found no significant differences in the prespecified subsidiary clinical outcomes of
245 cause-specific mortality (appendix p 40), use of ventilation, successful cessation of
246 invasive mechanical ventilation, or need for renal dialysis or haemofiltration (Table 2).
247 We observed no significant differences in the frequency of new cardiac arrhythmias
248 (appendix p 41). There was one report of a serious adverse reaction believed related to
249 azithromycin: a case of pseudomembranous colitis from which the patient recovered
250 with standard treatment.

251

252 **DISCUSSION**

253 The results of this large randomised trial show that azithromycin is not an effective
254 treatment for patients hospitalised with COVID-19. Allocation to azithromycin was not
255 associated with reductions in mortality, duration of hospitalisation or the risk of being
256 ventilated or dying for those not on ventilation at baseline. These results were
257 consistent across the prespecified subgroups of age, sex, ethnicity, duration of

Azithromycin for COVID-19

258 symptoms prior to randomisation, level of respiratory support at randomisation, use of
259 corticosteroids, and baseline predicted risk of death at randomisation.

260 Azithromycin was proposed as a treatment for COVID-19 based on its
261 immunomodulatory activity.⁷ Although no major organization or professional society has
262 recommended the routine use of azithromycin in COVID-19 unless there is evidence of
263 bacterial super-infection, it has nevertheless been used widely in COVID-19 patients,
264 particularly in combination with hydroxychloroquine.²⁰⁻²² Macrolides have long been
265 suggested as potential therapies for inflammatory viral pneumonias but this has been
266 based on in vitro, animal and observational data, with very little clinical trial evidence of
267 benefit.¹¹⁻¹³ The benefit of dexamethasone in COVID-19 patients requiring respiratory
268 support suggests that inflammation has a causal role in mortality.³ Noting that the
269 results were consistent regardless of whether patients were also being treated with a
270 corticosteroid or not, we conclude that the immunomodulatory properties of
271 azithromycin are either insufficient or off-target in COVID-19.

272 Macrolides are commonly used to treat bacterial infections of the lower respiratory tract
273 because of their good activity against Gram positive bacteria and atypical pathogens
274 such as *Mycoplasma pneumoniae* and *Legionella* species, and their excellent tissue
275 penetration. More than 75% of hospitalised COVID-19 patients are prescribed
276 antibiotics and the widespread clinical use of macrolides in COVID-19 is likely to be
277 driven largely by concerns of bacterial superinfection rather than purported
278 immunomodulatory activity.²³ It is therefore important to highlight that in patients with
279 moderate or severe COVID-19, who might be expected to experience some burden of

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Azithromycin for COVID-19

280 secondary bacterial lung infection, there was no observed clinical benefit of
281 azithromycin use. This lack of effect may either reflect the relatively low rate of
282 secondary bacterial infection in COVID-19 or the widespread use of other antibiotics
283 such as β -lactam antibiotics, which may have abrogated any anti-bacterial benefit of
284 allocation to azithromycin in this trial.^{24,25} Our results show that azithromycin confers no
285 clinical benefit in hospitalised COVID-19 patients, whether that be anti-inflammatory or
286 antimicrobial. Although we detected no harm to individual patients treated with
287 azithromycin, there is a risk of harm at a societal level from widespread use of
288 antimicrobial agents. Azithromycin is classified within the WHO Watch Group of
289 Antibiotics: antibiotics that have higher resistance potential and should be prioritized as
290 key targets of antimicrobial stewardship programs. In light of the new evidence from the
291 RECOVERY trial, the widespread use in COVID-19 patients of macrolides in particular
292 and antibiotics in general must be questioned.²⁶

293 Our trial has some limitations: Detailed information on laboratory markers of
294 inflammatory status, co-existent bacterial infection, or use of non-macrolide antibiotics
295 was not collected, nor was information on radiological or physiological outcomes. This
296 initial report is based on complete follow-up for the primary outcome in 73% of patients
297 (and partial follow-up for the remaining 27%). However, collection of outcome
298 information both through case report forms and linkage to routine NHS records is
299 ongoing and, based on previous reports from this trial, will deliver complete follow-up
300 information for over 99% of patients by early January 2021. However, additional follow-
301 up is unlikely to change the conclusion that azithromycin has no meaningful benefit for
302 hospitalised patients with COVID-19.

Azithromycin for COVID-19

303 Three other randomised controlled trials have assessed the efficacy of azithromycin for
304 the treatment of COVID-19 in hospitalised patients, all of which additionally treated
305 patients with hydroxychloroquine.¹⁵⁻¹⁷ The COALITION I and COALITION II trials found
306 that allocation of hospitalized patients with COVID-19 to azithromycin and
307 hydroxychloroquine, was not associated with any improvement in mortality, duration of
308 hospital stay, or clinical status as assessed using an ordinal outcome scale.^{15,16} A small
309 trial in Iran that randomised patients to hydroxychloroquine and lopinavir-ritonavir with
310 or without azithromycin also found no significant difference in mortality or intensive care
311 unit admission, but suggested a reduction in duration of hospital stay.¹⁷ The total
312 number of patients in all three prior trials combined was 1223, with 130 deaths. The
313 RECOVERY trial, with 7764 participants and 1483 deaths in this assessment of
314 azithromycin, is far better powered to detect modest treatment benefits; none were
315 observed.

316 At the time of writing, 24 trials evaluating the use of macrolides in COVID-19 patients
317 were registered in the WHO International Clinical Trials Registry Platform, of which two
318 (COALITION I and COALITION II, described above) have published results. Of the
319 remaining 22, 16 are studying macrolides in inpatients either alone or in combination
320 with other putative treatments, whilst 6 are studying non-hospitalised patients with
321 suspected or confirmed COVID-19.

322 Whilst our findings do not address the use of macrolides for the treatment of non-
323 hospitalised COVID-19 patients with early, mild disease, the results do show that
324 azithromycin is not an effective treatment for hospitalised COVID-19 patients.

Azithromycin for COVID-19

325

326 **Contributors**

327 This manuscript was initially drafted by PWH and MJL, further developed by the Writing
328 Committee, and approved by all members of the trial steering committee. PWH and MJL
329 vouch for the data and analyses, and for the fidelity of this report to the study protocol
330 and data analysis plan. PWH, MM, JKB, LCC, SNF, TJ, KJ, WSL, AM, KR, EJ, RH, and
331 MJL designed the trial and study protocol. MM, AR, G P-A, CB, BP, DC, AU, AA, ST,
332 BY, RB, SS, DM, RH, the Data Linkage team at the RECOVERY Coordinating Centre,
333 and the Health Records and Local Clinical Centre staff listed in the appendix collected
334 the data. ES, NS, and JRE did the statistical analysis. All authors contributed to data
335 interpretation and critical review and revision of the manuscript. PWH and JL had
336 access to the study data and had final responsibility for the decision to submit for
337 publication.

338

Azithromycin for COVID-19

339 **Writing Committee (on behalf of the RECOVERY Collaborative Group):**

340 Professor Peter W Horby PhD FRCP,^{a,*} Alistair Roddick MBBS,^{b,c,*} Enti Spata,^{b,d,*}
341 Natalie Staplin PhD,^{b,d} Professor Jonathan R Emberson PhD,^{b,d} Guilherme Pessoa-
342 Amorim MD,^{b,e} Leon Peto PhD,^{a,c} Mark Campbell FRCPATH,^{b,c} Professor Christopher
343 Brightling FRCP,^f Benjamin Prudon FRCP,^f David Chadwick PhD,^h Andrew Ustianowski
344 PhD,ⁱ Abdul Ashish MD,^j Stacy Todd PhD,^k Bryan Yates MRCP,^l Robert Buttery PhD,^m
345 Stephen Scott PhD,ⁿ Diego Maseda MD,^o J Kenneth Baillie MD PhD,^p Professor Maya
346 H Buch PhD FRCP,^q Professor Lucy C Chappell PhD,^r Professor Jeremy Day PhD
347 FRCP,^{a,s} Professor Saul N Faust PhD FRCPCH,^t Professor Thomas Jaki PhD,^{u,v} Katie
348 Jeffery PhD FRCP FRCPATH,^c Professor Edmund Juszczak MSc,^w Professor Wei Shen
349 Lim FRCP,^{w,x} Professor Alan Montgomery PhD,^w Professor Andrew Mumford PhD,^y
350 Kathryn Rowan PhD,^z Professor Guy Thwaites PhD FRCP,^{a,s} Marion Mafham MD,^{b,t}
351 Professor Richard Haynes DM,^{b,d,t} Professor Martin J Landray PhD FRCP.^{b,d,e,t}

352

353 ^a Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

354 ^b Nuffield Department of Population Health, University of Oxford, Oxford, United
355 Kingdom

356 ^c Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

357 ^d MRC Population Health Research Unit, University of Oxford, Oxford, United Kingdom

Azithromycin for COVID-19

- 358 ^e NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS
359 Foundation Trust, Oxford, United Kingdom
- 360 ^f Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of
361 Leicester, Leicester, United Kingdom
- 362 ^g Department of Respiratory Medicine, North Tees & Hartlepool NHS Foundation Trust,
363 Stockton-on-Tees, United Kingdom
- 364 ^h Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, United
365 Kingdom
- 366 ⁱ North Manchester General Hospital, Pennine Acute Hospitals NHS Trust, Bury, United
367 Kingdom
- 368 ^j Wrightington Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom
- 369 ^k Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom
- 370 ^l Northumbria Healthcare NHS Foundation Trust, North Tyneside, United Kingdom
- 371 ^m North West Anglia NHS Foundation Trust, Peterborough, United Kingdom
- 372 ⁿ The Countess of Chester Hospital NHS Foundation Trust, Chester, United Kingdom
- 373 ^o Mid Cheshire Hospitals NHS Foundation Trust, Crewe, United Kingdom
- 374 ^p Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Azithromycin for COVID-19

375 ^q Centre for Musculoskeletal Research, University of Manchester, Manchester, and
376 NIHR Manchester Biomedical Research Centre, United Kingdom.

377 ^r School of Life Course Sciences, King's College London, London, United Kingdom

378 ^s Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam

379 ^t NIHR Southampton Clinical Research Facility and Biomedical Research Centre,
380 University Hospital Southampton NHS Foundation Trust and University of Southampton,
381 Southampton, United Kingdom

382 ^u Department of Mathematics and Statistics, Lancaster University, Lancaster, United
383 Kingdom

384 ^v MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom

385 ^w School of Medicine, University of Nottingham, Nottingham, United Kingdom

386 ^x Respiratory Medicine Department, Nottingham University Hospitals NHS Trust,
387 Nottingham, United Kingdom

388 ^y School of Cellular and Molecular Medicine, University of Bristol, Bristol, United
389 kingdom

390 ^z Intensive Care National Audit & Research Centre, London, United Kingdom

391 ^{*}, [†] equal contribution

392

393

Azithromycin for COVID-19

394 **Data Monitoring Committee**

395 Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Laloo, Ian
396 Roberts, Janet Wittes.

397 **Declaration of interests**

398 The authors have no conflict of interest or financial relationships relevant to the
399 submitted work to disclose. No form of payment was given to anyone to produce the
400 manuscript. All authors have completed and submitted the ICMJE Form for Disclosure
401 of Potential Conflicts of Interest. The Nuffield Department of Population Health at the
402 University of Oxford has a staff policy of not accepting honoraria or consultancy fees
403 directly or indirectly from industry (see [https://www.ndph.ox.ac.uk/files/about/ndph-](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)
404 [independence-of-research-policy-jun-20.pdf](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)).

405 **Data sharing**

406 The protocol, consent form, statistical analysis plan, definition & derivation of clinical
407 characteristics & outcomes, training materials, regulatory documents, and other relevant
408 study materials are available online at www.recoverytrial.net. As described in the
409 protocol, the trial Steering Committee will facilitate the use of the study data and
410 approval will not be unreasonably withheld. Deidentified participant data will be made
411 available to bona fide researchers registered with an appropriate institution within 3
412 months of publication. However, the Steering Committee will need to be satisfied that
413 any proposed publication is of high quality, honours the commitments made to the study
414 participants in the consent documentation and ethical approvals, and is compliant with

Azithromycin for COVID-19

415 relevant legal and regulatory requirements (e.g. relating to data protection and privacy).
416 The Steering Committee will have the right to review and comment on any draft
417 manuscripts prior to publication. Data will be made available in line with the policy and
418 procedures described at: <https://www.ndph.ox.ac.uk/data-access>. Those wishing to
419 request access should complete the form at
420 https://www.ndph.ox.ac.uk/files/about/data_access_enquiry_form_13_6_2019.docx
421 and e-mailed to: data.access@ndph.ox.ac.uk

422

423 **Acknowledgements**

424 Above all, we would like to thank the thousands of patients who participated in this
425 study. We would also like to thank the many doctors, nurses, pharmacists, other allied
426 health professionals, and research administrators at 176 NHS hospital organisations
427 across the whole of the UK, supported by staff at the National Institute of Health
428 Research (NIHR) Clinical Research Network, NHS DigiTrials, Public Health England,
429 Department of Health & Social Care, the Intensive Care National Audit & Research
430 Centre, Public Health Scotland, National Records Service of Scotland, the Secure
431 Anonymised Information Linkage (SAIL) at University of Swansea, and the NHS in
432 England, Scotland, Wales and Northern Ireland.

433 The RECOVERY trial is supported by a grant to the University of Oxford from UK
434 Research and Innovation/NIHR (Grant reference: MC_PC_19056) and by core funding
435 provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill and Melinda
436 Gates Foundation, the Department for International Development, Health Data Research

Azithromycin for COVID-19

437 UK, the Medical Research Council Population Health Research Unit, the NIHR Health
438 Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit
439 Support Funding. TJ is supported by a grant from UK Medical Research Council
440 (MC_UU_0002/14) and an NIHR Senior Research Fellowship (NIHR-SRF-2015-08-
441 001). WSL is supported by core funding provided by NIHR Nottingham Biomedical
442 Research Centre. Abbvie contributed some supplies of lopinavir-ritonavir for use in this
443 study. Tocilizumab was provided free of charge for this study by Roche Products
444 Limited. REGN-COV2 was provided free of charge for this study by Regeneron.

445 The views expressed in this publication are those of the authors and not necessarily
446 those of the NHS, the National Institute for Health Research or the Department of
447 Health and Social Care.

448 **Conflicts of interest**

449 The authors have no conflict of interest or financial relationships relevant to the
450 submitted work to disclose. No form of payment was given to anyone to produce the
451 manuscript. All authors have completed and submitted the ICMJE Form for Disclosure
452 of Potential Conflicts of Interest. The Nuffield Department of Population Health at the
453 University of Oxford has a staff policy of not accepting honoraria or consultancy fees
454 directly or indirectly from industry (see [https://www.ndph.ox.ac.uk/files/about/ndph-
455 independence-of-research-policy-jun-20.pdf](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)).

456

Azithromycin for COVID-19

457 **References**

- 458 1. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in
459 hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:
460 prospective observational cohort study. *Bmj* 2020; **369**: m1985.
- 461 2. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a
462 series of COVID-19 cases from northern Italy: a two-centre descriptive study. *Lancet*
463 *Infect Dis* 2020.
- 464 3. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients
465 with Covid-19 - Preliminary Report. *N Engl J Med* 2020.
- 466 4. Sterne JAC, Diaz J, Villar J, et al. Corticosteroid therapy for critically ill patients
467 with COVID-19: A structured summary of a study protocol for a prospective meta-
468 analysis of randomized trials. *Trials* 2020; **21**(1): 734.
- 469 5. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides
470 as immunomodulatory medications. *Clin Microbiol Rev* 2010; **23**(3): 590-615.
- 471 6. Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory
472 medications: proposed mechanisms of action. *Pharmacol Ther* 2008; **117**(3): 393-405.
- 473 7. Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The Immunomodulatory Effects
474 of Macrolides-A Systematic Review of the Underlying Mechanisms. *Front Immunol*
475 2018; **9**: 302.
- 476 8. Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic
477 respiratory disease. *Eur Respir J* 2013; **42**(1): 239-51.
- 478 9. Smith D, Du Rand IA, Addy C, et al. British Thoracic Society guideline for the use
479 of long-term macrolides in adults with respiratory disease. *BMJ Open Respir Res* 2020;
480 **7**(1).
- 481 10. Touret F, Gilles M, Barral K, et al. In vitro screening of a FDA approved chemical
482 library reveals potential inhibitors of SARS-CoV-2 replication. *Sci Rep* 2020; **10**(1):
483 13093.
- 484 11. Oliver ME, Hinks TSC. Azithromycin in viral infections. *Rev Med Virol* 2020:
485 e2163.
- 486 12. Hui DS, Lee N, Chan PK, Beigel JH. The role of adjuvant immunomodulatory
487 agents for treatment of severe influenza. *Antiviral Res* 2018; **150**: 202-16.
- 488 13. Lee N, Wong CK, Chan MCW, et al. Anti-inflammatory effects of adjunctive
489 macrolide treatment in adults hospitalized with influenza: A randomized controlled trial.
490 *Antiviral Res* 2017; **144**: 48-56.

Azithromycin for COVID-19

- 491 14. Hung IFN, To KKW, Chan JFW, et al. Efficacy of Clarithromycin-Naproxen-
492 Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza
493 A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial. *Chest*
494 2017; **151**(5): 1069-80.
- 495 15. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without
496 Azithromycin in Mild-to-Moderate Covid-19. *New England Journal of Medicine* 2020.
- 497 16. Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to
498 standard of care versus standard of care alone in the treatment of patients admitted to
499 the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.
500 *Lancet* 2020; **396**(10256): 959-67.
- 501 17. Sekhavati E, Jafari F, SeyedAlinaghi S, et al. Safety and effectiveness of
502 azithromycin in patients with COVID-19: An open-label randomised trial. *Int J Antimicrob*
503 *Agents* 2020; **56**(4): 106143.
- 504 18. Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hospitalized
505 Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled
506 trial. *medRxiv* 2020: 2020.07.15.20151852.
- 507 19. Recovery Collaborative Group, Horby PW, Mafham M, et al. Lopinavir-ritonavir in
508 patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled,
509 open-label, platform trial. *Lancet* 2020.
- 510 20. Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, Caramori G, Trifiro G.
511 Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence
512 and Prescribing Guidelines. *Drug Saf* 2020; **43**(8): 691-8.
- 513 21. SERMO. Sermo reports jury is still out on Remdesivir. 2020.
514 [https://www.sermo.com/press-releases/sermo-reports-jury-is-still-out-on-remdesivir-31-](https://www.sermo.com/press-releases/sermo-reports-jury-is-still-out-on-remdesivir-31-of-physicians-who-have-used-remdesivir-rate-it-as-highly-effective-31-rate-it-with-low-effectiveness-38-rate-it-as-somewhere-in-the-middle/)
515 [of-physicians-who-have-used-remdesivir-rate-it-as-highly-effective-31-rate-it-with-low-](https://www.sermo.com/press-releases/sermo-reports-jury-is-still-out-on-remdesivir-31-of-physicians-who-have-used-remdesivir-rate-it-as-highly-effective-31-rate-it-with-low-effectiveness-38-rate-it-as-somewhere-in-the-middle/)
516 [effectiveness-38-rate-it-as-somewhere-in-the-middle/](https://www.sermo.com/press-releases/sermo-reports-jury-is-still-out-on-remdesivir-31-of-physicians-who-have-used-remdesivir-rate-it-as-highly-effective-31-rate-it-with-low-effectiveness-38-rate-it-as-somewhere-in-the-middle/).
- 517 22. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in
518 Hospitalized Patients with Covid-19. *N Engl J Med* 2020.
- 519 23. Hall M, Pritchard M, Dankwa EA, et al. ISARIC Clinical Data Report 20
520 November 2020. *medRxiv* 2020: 2020.07.17.20155218.
- 521 24. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19:
522 a systematic review and meta-analysis. *J Infect* 2020; **81**(2): 266-75.
- 523 25. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and Fungal Coinfection in
524 Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial
525 Prescribing. *Clin Infect Dis* 2020; **71**(9): 2459-68.

It is made available under a [CC-BY 4.0 International license](#) .

Azithromycin for COVID-19

- 526 26. Ginsburg AS, Klugman KP. COVID-19 pneumonia and the appropriate use of
527 antibiotics. *Lancet Glob Health* 2020; **8**(12): e1453-e4.
528
529

Azithromycin for COVID-19

582 **Table 1: Baseline characteristics**

| | Treatment allocation | |
|---|--------------------------|------------------------|
| | Azithromycin (n=2582) | Usual care (n=5182) |
| Age, years | 65.4 (15.6) | 65.2 (15.7) |
| <70* | 1508 (58%) | 3015 (58%) |
| ≥70 to <80 | 615 (24%) | 1167 (23%) |
| ≥80 | 459 (18%) | 1000 (19%) |
| Sex | | |
| Male | 1603 (62%) | 3216 (62%) |
| Female† | 979 (38%) | 1966 (38%) |
| Ethnicity | | |
| White | 1867 (72%) | 3773 (73%) |
| Black, Asian, and minority ethnic | 363 (14%) | 708 (14%) |
| Unknown | 352 (14%) | 701 (14%) |
| Number of days since symptom onset | 8 (5-11) | 8 (5-11) |
| Number of days since admission to hospital | 2 (1-4) | 2 (1-4) |
| Respiratory support received | | |
| No oxygen received | 490 (19%) | 918 (18%) |
| Oxygen only ‡ | 1940 (75%) | 3964 (76%) |
| Invasive mechanical ventilation | 152 (6%) | 300 (6%) |
| Previous diseases | | |
| Diabetes | 700 (27%) | 1433 (28%) |
| Heart disease | 693 (27%) | 1350 (26%) |
| Chronic lung disease | 621 (24%) | 1314 (25%) |
| Tuberculosis | 3 (<1%) | 16 (<1%) |
| HIV | 7 (<1%) | 22 (<1%) |
| Severe liver disease § | 45 (2%) | 65 (1%) |
| Severe kidney impairment ¶ | 155 (6%) | 334 (6%) |
| Any of the above | 1507 (58%) | 3014 (58%) |
| Use of corticosteroids | | |
| Yes | 1567 (61%) | 3172 (61%) |
| No | 183 (7%) | 399 (8%) |
| Unknown [^] | 832 (32%) | 1611 (31%) |
| Severe acute respiratory syndrome coronavirus 2 test result | | |
| Positive | 2282 (88%) | 4634 (89%) |
| Negative | 195 (8%) | 371 (7%) |
| Unknown | 105 (4%) | 177 (3%) |

Data are mean (SD), n (%), or median (IQR). * Includes 26 children (<18 years).
 † Includes 25 pregnant women. ‡ Includes non-invasive ventilation. § Defined as requiring ongoing specialist care. ¶ Defined as estimated glomerular filtration rate <30 mL/min per 1.73 m². [^] Information on use of corticosteroids was collected from 18 June 2020 onwards following announcement of the results of the dexamethasone comparison from the RECOVERY trial.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Azithromycin for COVID-19

584 **Table 2: Effect of allocation to azithromycin on key study outcomes**

| | Treatment allocation | | RR (95% CI) | p-value |
|---|--------------------------|------------------------|------------------|---------|
| | Azithromycin (n=2582) | Usual care (n=5182) | | |
| Primary outcome: | | | | |
| 28-day mortality | 496 (19%) | 997 (19%) | 1.00 (0.90-1.12) | 0.99 |
| Secondary outcomes: | | | | |
| Median time to being discharged alive, days | 12 | 13 | | |
| Discharged from hospital within 28 days | 1554 (60%) | 3066 (59%) | 1.03 (0.97-1.10) | 0.29 |
| Receipt of invasive mechanical ventilation or death* | 517/2430 (21%) | 1069/4882 (22%) | 0.97 (0.89-1.07) | 0.54 |
| Invasive mechanical ventilation | 154/2430 (6%) | 325/4882 (7%) | 0.95 (0.79-1.15) | 0.60 |
| Death | 442/2430 (18%) | 891/4882 (18%) | 1.00 (0.90-1.10) | 0.95 |
| Subsidiary clinical outcomes | | | | |
| Receipt of ventilation † | 27/490 (6%) | 50/918 (5%) | 1.01 (0.64-1.59) | 0.96 |
| Non-invasive ventilation | 24/490 (5%) | 43/918 (5%) | 1.05 (0.64-1.70) | 0.86 |
| Invasive mechanical ventilation | 8/490 (2%) | 11/918 (1%) | 1.36 (0.55-3.37) | 0.50 |
| Successful cessation of invasive mechanical ventilation ‡ | 42/152 (28%) | 95/300 (32%) | 0.84 (0.59-1.20) | 0.33 |
| Use of haemodialysis or haemofiltration § | 79/2548 (3%) | 158/5125 (3%) | 1.01 (0.77-1.31) | 0.97 |

Data are n (%) or n/N (%), unless otherwise indicated. RR=rate ratio for the outcomes of 28-day mortality, hospital discharge and successful cessation of invasive mechanical ventilation, and risk ratio for other outcomes. * Analyses exclude those on invasive mechanical ventilation at randomisation. † Analyses exclude those on any form of ventilation at randomisation. ‡ Analyses restricted to those on invasive mechanical ventilation at randomisation. § Analyses exclude those on haemodialysis or haemofiltration at randomisation.

585

586

Azithromycin for COVID-19

560 **Figures**

561 **Figure 1: Trial profile**

562 ITT=intention to treat. # Number recruited overall during period that adult participants
563 could be recruited into azithromycin comparison. * 1986/2582 (77%) and 3924/5182
564 (76%) patients have a completed follow-up form at time of analysis. 3994 patients were
565 additionally randomised to convalescent plasma vs REGN-COV2 vs usual care (1320
566 [51%] patients allocated to azithromycin vs 2674 [52%] patients allocated usual care)
567 and 975 patients were additionally randomised to aspirin vs usual care (323 [13%]
568 patients allocated to azithromycin vs 652 [13%] patients allocated usual care. † Includes
569 197/2582 (7.6%) patients in the azithromycin arm and 446/5182 (8.6%) patients in the
570 usual care arm allocated to tocilizumab.

571 **Figure 2: Effect of allocation to azithromycin on 28-day mortality**

572 **Figure 3: Effect of allocation to azithromycin on 28-day mortality by baseline** 573 **characteristics**

574 Subgroup-specific rate ratio estimates are represented by squares (with areas of the
575 squares proportional to the amount of statistical information) and the lines through them
576 correspond to the 95% CIs. The ethnicity and days since onset subgroups exclude
577 those with missing data, but these patients are included in the overall summary
578 diamond. * Includes patients receiving non-invasive ventilation. Information on use of
579 corticosteroids was collected from 18 June 2020 onwards following announcement of
580 the results of the dexamethasone comparison from the RECOVERY trial.

581

Figure 1: Trial profile

medRxiv preprint doi: <https://doi.org/10.1101/2020.12.10.20245944>; this version posted December 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).





Figure 2: Effect of allocation to azithromycin on 28-day mortality

medRxiv preprint doi: <https://doi.org/10.1101/2020.12.10.20245944>; this version posted December 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



| Number at risk | 0 | 7 | 14 | 21 | 28 |
|----------------|------|------|------|------|------|
| Active | 2582 | 2255 | 1957 | 1802 | 1729 |
| Control | 5182 | 4550 | 3947 | 3604 | 3434 |

Figure 3: Effect of allocation to azithromycin on 28-day mortality by baseline characteristics

